KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short term Debt (2016 - 2025)

Sarepta Therapeutics (SRPT) has 11 years of Short term Debt data on record, last reported at $36.0 million in Q3 2025.

  • For Q3 2025, Short term Debt fell 60.7% year-over-year to $36.0 million; the TTM value through Sep 2025 reached $36.0 million, down 60.7%, while the annual FY2023 figure was $105.5 million, N/A changed from the prior year.
  • Short term Debt reached $36.0 million in Q3 2025 per SRPT's latest filing, down from $91.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $105.6 million in Q1 2024 and bottomed at $36.0 million in Q3 2025.
  • Average Short term Debt over 3 years is $86.0 million, with a median of $91.6 million recorded in 2024.
  • The widest YoY moves for Short term Debt: up 60.7% in 2025, down 60.7% in 2025.
  • A 3-year view of Short term Debt shows it stood at $105.5 million in 2023, then fell by 13.17% to $91.6 million in 2024, then tumbled by 60.7% to $36.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $36.0 million in Q3 2025, $91.6 million in Q3 2024, and $91.5 million in Q2 2024.